{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-052142","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.337262+00:00","generated_at":"2026-06-03T00:49:09.367957+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dyne Therapeutics Q1 net loss $65.6M; cash $453.5M; clinical trials on track for H2 data","bullets":["Net loss $65.6M ($0.81 per share) vs $44.2M ($0.78) in Q1 2023.","Cash, equivalents and marketable securities $453.5M; expects funding through 2025.","R&D expenses $44.5M (up 19% YoY); G&A expenses $24.6M (up 211% YoY) largely due to new CEO.","John Cox appointed CEO and President in March 2024.","Phase 1/2 ACHIEVE (DM1) and DELIVER (DMD) trials progressing; additional data expected H2 2024 with registrational cohorts by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-052142","json":"https://secwatch.observer/filing/0000950170-24-052142.json","markdown":"https://secwatch.observer/filing/0000950170-24-052142.md","text":"https://secwatch.observer/filing/0000950170-24-052142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024052142/0000950170-24-052142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024052142/dyn-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:49:09.367957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf149a6886e19d755134c64e7c522486cb7c9409","claim":"Dyne Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $65.6 million, or $0.81 per basic and diluted share, EPS $0.81 per basic and diluted share.","evidence_excerpt":"Net loss for the quarter ended March 31, 2024 was $65.6 million, or $0.81 per basic and diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024052142/0000950170-24-052142-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$65.6 million, or $0.81 per basic and diluted share"},{"label":"EPS","value":"$0.81 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}